Доступ предоставлен для: Guest
Портал Begell Электронная Бибилиотека e-Книги Журналы Справочники и Сборники статей Коллекции
Critical Reviews™ in Therapeutic Drug Carrier Systems
Импакт фактор: 2.9 5-летний Импакт фактор: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Печать: 0743-4863
ISSN Онлайн: 2162-660X

Том 36, 2019 Том 35, 2018 Том 34, 2017 Том 33, 2016 Том 32, 2015 Том 31, 2014 Том 30, 2013 Том 29, 2012 Том 28, 2011 Том 27, 2010 Том 26, 2009 Том 25, 2008 Том 24, 2007 Том 23, 2006 Том 22, 2005 Том 21, 2004 Том 20, 2003 Том 19, 2002 Том 18, 2001 Том 17, 2000 Том 16, 1999 Том 15, 1998 Том 14, 1997 Том 13, 1996 Том 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2015010174
pages 215-245

Polymer-Drug Conjugates for Anticancer Drug Delivery

Saurabh Wadhwa
Regeneron Pharmaceuticals, Tarrytown, New York
Russell J. Mumper
Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, Center for Nanotechnology in Drug Delivery, and UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina

Краткое описание

Polymer-drug conjugates (PDCs) are drug delivery systems where one or more drug(s) are covalently attached to the functional groups of the polymer directly or through a spacer. Several anticancer drugs that have been used to synthesize PDCs are currently under clinical trials. PDCs have shown enhanced tumor accumulation, increased therapeutic index, and prolonged circulation, accompanied by a sustained release of the bound drug. Distinct cell uptake mechanisms make PDCs less sensitive to efflux pumps associated with the development of multi-drug resistance. However, the effectiveness of PDCs as a delivery system primarily depends on the drug, polymer, type of linkage, and presence of targeting groups. Due to the availability of different functional groups and spacers, it is possible to control drug release as well as multi-functionalize PDCs, thereby increasing their versatility as drug carriers. Furthermore, active tumor uptake may be achieved by using the concept of drug targeting. However, functionalization alters the in vivo behavior of the polymer, signifying the evaluation of safety and effectiveness of PDCs. Several PDCs are currently being tested in different phases of clinical trials. This review focuses on critical aspects in the design of PDCs when used in cancer drug delivery.

Ключевые слова: drug conjugation, cancer, covalent, spacer, sustained release

Articles with similar content:

Dendrimers for Therapeutic Delivery: Compositions, Characterizations, and Current Status
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.36, 2019, issue 4
Pradeep Kumar, Kalpana Nagpal, Sourav Thakur, Anand Mohan
Cracking the Junction: Update on the Progress of Gastrointestinal Absorption Enhancement in the Delivery of Poorly Absorbed Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.25, 2008, issue 2
David J. Brayden, Siobhan McClean, Sam Maher, Linda Feighery
Penetration Enhancement of Transdermal Delivery—Current Permutations and Limitations
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.21, 2004, issue 2
Chad G. Azzi, Jin Zhang, Carryn H. Purdon, Howard I. Maibach, Eric W. Smith
Peptide and Protein Delivery Using New Drug Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.30, 2013, issue 4
Ashish Jain, Satish Shilpi, Pooja Hurkat, Aviral Jain, Arvind Gulbake, Sanjay Kumar Jain
Factors Affecting Drug and Gene Delivery: Effects of Interaction with Blood Components
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.19, 2002, issue 3
Makiya Nishikawa, Mitsuru Hashida, Praneet Opanasopit